Sangamo Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Sangamo Therapeutics şirketinin toplam hissedar öz sermayesi $39.1M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $111.3M ve $72.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$39.20m
Eşitlik	US$39.13m
Toplam yükümlülükler	US$72.13m
Toplam varlıklar	US$111.26m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GBY 'nin kısa vadeli varlıkları ( $58.1M ) kısa vadeli yükümlülüklerini ( $43.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: GBY şirketinin kısa vadeli varlıkları ( $58.1M ) uzun vadeli yükümlülüklerini ( $29.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GBY borçsuzdur.

Borcun Azaltılması: GBY son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: GBY şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: GBY tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sangamo Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Sangamo Therapeutics, Inc. Receives A Deficiency Notice from Nasdaq

Sangamo Therapeutics, Inc. Receives A Deficiency Notice from Nasdaq

Recent updates

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.59 loss in 3Q 2023)

New major risk - Revenue and earnings growth

Sangamo Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

New major risk - Financial position

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.66 loss in 2Q 2023)

Sangamo Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

New minor risk - Market cap size

New major risk - Financial position

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)

Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024

Sangamo Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Sangamo Therapeutics, Inc. Receives A Deficiency Notice from Nasdaq

Sangamo Therapeutics, Inc. Receives A Deficiency Notice from Nasdaq

Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Market cap size

Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million.

Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million.

Full year 2023 earnings released: US$1.48 loss per share (vs US$1.25 loss in FY 2022)

Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023

Sangamo Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920

Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial

Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.34 loss in 3Q 2022)

Sangamo Therapeutics, Inc. Reports Impairment Charges for the Three Months Ended September 30, 2023

Sangamo Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy

New minor risk - Market cap size

Now 20% undervalued after recent price drop

New major risk - Financial position

Second quarter 2023 earnings released: US$0.66 loss per share (vs US$0.29 loss in 2Q 2022)

Sangamo Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Sangamo Therapeutics, Inc. Appoints Lisa Rojkjaer as Chief Medical Officer

First quarter 2023 earnings released: EPS: US$0.13 (vs US$0.30 loss in 1Q 2022)

Full year 2022 earnings released: US$1.25 loss per share (vs US$1.23 loss in FY 2021)

Sangamo Therapeutics, Inc. Announces Directors Appointment

Insufficient new directors

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.33 loss in 3Q 2021)

Sangamo Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Sangamo Therapeutics, Inc. Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Nine Patients

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated A-Gal A Enzyme Activity in Five Longest Treated Patients

Sangamo Therapeutics, Inc Announces Executive Changes

Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.33 loss in 2Q 2021)

Sangamo Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.32 loss in 1Q 2021)

Sangamo Therapeutics, Inc. to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

High number of new and inexperienced directors

Saira Ramasastry Decides Not to Stand for Re-Election as A Member of the Board of Directors of Sangamo Therapeutics, Inc

Sangamo Therapeutics, Inc., Annual General Meeting, May 24, 2022

Sangamo Therapeutics, Inc. Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation

Sangamo Therapeutics, Inc. Doses First Patient in Its Phase 1/2 STEADFAST Clinical Study Evaluating TX200

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sangamo Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Sangamo Therapeutics, Inc. Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated A-Gal A Enzyme Activity in Patients with Fabry Disease

Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.011 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.26 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.32 loss per share (vs US$0.37 loss in 1Q 2020)

Executive VP recently sold €62k worth of stock

Sangamo Therapeutics, Inc. Appoints Prathyusha Duraibabu as Principal Financial Officer

Revenue misses expectations

Full year 2020 earnings released: US$0.90 loss per share (vs US$0.85 loss in FY 2019)

Sangamo Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Executive VP & CFO has left the company

Sangamo Therapeutics Appoints Rob Schott as Senior Vice President and Head of Development

Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee, Effective February 1, 2021

New 90-day low: €7.68

Third quarter 2020 earnings released: US$0.011 loss per share

Revenue beats expectations

Sangamo Therapeutics, Inc. to Report Q3, 2020 Results on Nov 04, 2020

Pfizer Inc. and Sangamo Therapeutics, Inc. Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment

New 90-day low: €7.84

Sangamo Therapeutics, Inc. Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019

Sangamo BioSciences, Inc. has entered into a definitive asset purchase agreement to acquire angiogenesis program from and Edwards Lifesciences Corporation for $7.5 million.